ONS ONCC CHEMO RENEWAL EXAM (ACTUAL 2025/2026)
QUESTIONS AND ANSWERS GRADED A+ LATEST
Neoadjuvant therapy does not increase survival when compared to
adjuvant therapy. It only changes the timing of treatment and can
change surgical options if the tumor is shrunk enough. If this occurs,
the patient may only require a lumpectomy plus radiation therapy
instead of needing a mastectomy
Main benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and
mortality in the older patient. This assessment tool would evaluate
and include the following areas: functional status, socioeconomic
issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN
Older Adult Oncology Guidelines, version 1.2015).
Due to Mrs. Turner's age and comorbidities, her oncologist performs a
comprehensive geriatric assessment. You know that this assessment
covers all but which of the following:
65
The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age ______and older and as the oncology world ages,
nearly half (46%) of cancer survivors are 70 years of age or older
,Effectiveness Unlikely:
Colony Stimulating Factors By Intravenous Rather Than
Subcutaneous Route
Frequent IV Tubing and Component Changes
Restriction of Fresh Fruits and Vegetables
Not Recommended for Practice:
Extended Post-Operative Antibiotics
Implantable Gentamycin Sponge
Use of Live Attenuated Vaccines
Prevention on Infections: Practices No Long Recommended
Per the NCCN Guidelines
(http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growt
h.pdf), because of Mrs. Turner's age ≥ 65 as well as a previous
neutropenic episode, she would be a candidate to receive a GCSF. Her
febrile neutropenic episode requiring hospitalization puts her at high
risk for additional neutropenia.
Which of the following do you feel will be done with the remaining
cycles of chemotherapy to hopefully prevent Mrs. Turner from having
additional problems with neutropenia?
full dose
, Evidence shows that older patients with cancer can safely obtain the
same treatment benefits as younger patients when they receive
________ standard chemotherapy regimens. Many physicians are
reluctant to give full-dose chemotherapy to older adults perhaps due
to of fear of adverse events like febrile neutropenia. Suboptimal
dosing from increasing the length of time between cycles or from
dose reduction is a serious issue because large, randomized clinical
trials have demonstrated that the delivery of lower doses or shorter
courses of chemotherapy can reduce overall survival in older patients
with breast cancer or lymphoma
85%
Amgen (2007) defines RDI as "is a quantification of how closely an
administered course of chemotherapy treatment adheres to a specific
regimen." Three separate clinical trials evaluating outcomes in
patients with breast cancer related to RDI have demonstrated
improved overall survival and 10-year disease free survival in patients
who receive a RDI > or = ____?_____
Per the prescribing information for Perjeta
(http://www.gene.com/download/pdf/perjeta_prescribing.pdf) it states
to assess LVEF prior to initiation of PERJETA and at regular
intervals (every six weeks in the neoadjuvant setting) during treatment
to ensure that LVEF is within the institution's normal limits. Mrs.
Turner's chemotherapy is given every 3 weeks so she should have her
LVEF evaluated prior to cycle #3. If Mrs. Turner was receiving
trastuzumab without pertuzumab, the recommendation per the
prescribing information for Herceptin
(http://www.gene.com/download/pdf/herceptin_prescribing.pdf) is to
monitor baseline LVEF measurement immediately prior to initiation
QUESTIONS AND ANSWERS GRADED A+ LATEST
Neoadjuvant therapy does not increase survival when compared to
adjuvant therapy. It only changes the timing of treatment and can
change surgical options if the tumor is shrunk enough. If this occurs,
the patient may only require a lumpectomy plus radiation therapy
instead of needing a mastectomy
Main benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and
mortality in the older patient. This assessment tool would evaluate
and include the following areas: functional status, socioeconomic
issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN
Older Adult Oncology Guidelines, version 1.2015).
Due to Mrs. Turner's age and comorbidities, her oncologist performs a
comprehensive geriatric assessment. You know that this assessment
covers all but which of the following:
65
The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age ______and older and as the oncology world ages,
nearly half (46%) of cancer survivors are 70 years of age or older
,Effectiveness Unlikely:
Colony Stimulating Factors By Intravenous Rather Than
Subcutaneous Route
Frequent IV Tubing and Component Changes
Restriction of Fresh Fruits and Vegetables
Not Recommended for Practice:
Extended Post-Operative Antibiotics
Implantable Gentamycin Sponge
Use of Live Attenuated Vaccines
Prevention on Infections: Practices No Long Recommended
Per the NCCN Guidelines
(http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growt
h.pdf), because of Mrs. Turner's age ≥ 65 as well as a previous
neutropenic episode, she would be a candidate to receive a GCSF. Her
febrile neutropenic episode requiring hospitalization puts her at high
risk for additional neutropenia.
Which of the following do you feel will be done with the remaining
cycles of chemotherapy to hopefully prevent Mrs. Turner from having
additional problems with neutropenia?
full dose
, Evidence shows that older patients with cancer can safely obtain the
same treatment benefits as younger patients when they receive
________ standard chemotherapy regimens. Many physicians are
reluctant to give full-dose chemotherapy to older adults perhaps due
to of fear of adverse events like febrile neutropenia. Suboptimal
dosing from increasing the length of time between cycles or from
dose reduction is a serious issue because large, randomized clinical
trials have demonstrated that the delivery of lower doses or shorter
courses of chemotherapy can reduce overall survival in older patients
with breast cancer or lymphoma
85%
Amgen (2007) defines RDI as "is a quantification of how closely an
administered course of chemotherapy treatment adheres to a specific
regimen." Three separate clinical trials evaluating outcomes in
patients with breast cancer related to RDI have demonstrated
improved overall survival and 10-year disease free survival in patients
who receive a RDI > or = ____?_____
Per the prescribing information for Perjeta
(http://www.gene.com/download/pdf/perjeta_prescribing.pdf) it states
to assess LVEF prior to initiation of PERJETA and at regular
intervals (every six weeks in the neoadjuvant setting) during treatment
to ensure that LVEF is within the institution's normal limits. Mrs.
Turner's chemotherapy is given every 3 weeks so she should have her
LVEF evaluated prior to cycle #3. If Mrs. Turner was receiving
trastuzumab without pertuzumab, the recommendation per the
prescribing information for Herceptin
(http://www.gene.com/download/pdf/herceptin_prescribing.pdf) is to
monitor baseline LVEF measurement immediately prior to initiation
